Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care 19CP02 for relapsed/refractory B-cell non-Hodgkin lymphoma
NL-OMON51902Phase 2Recruiting
- Sponsor
- Galapagos NV
- Start
- Mar 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GLPG5201 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more, sponsored by Galapagos NV. Primary endpoints: Incidence of adverse events and dose-limiting toxicities and Objective response rate. Started Mar 2022; status: recruiting.
02
Drugs
GLPG5201
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON51902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51902.